 Today, Alnylam Pharmaceuticals NASDAQ: ALNY revealed positive top-line results for the companys transthyretin-mediated amyloidosis treatment, patisiran. Alnylams drug reportedly met its primary endpoint for selected trial participants, and consequently, ALNY stock is roaring higher today. 